Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
UBP 302Cat. No. 2079 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: (S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione |
Biological Activity
Selective and potent GLUK5 (GluR5)-subunit containing kainate receptor antagonist (apparent KD = 402 nM); active enantiomer of UBP 296 (Cat. No. 2078). Displays ~ 260-fold selectivity over AMPA receptors. UBP 296 displays ~ 90-fold selectivity over recombinant human GLUK6- and GLUK2-containing kainate receptors, has little or no action at NMDA or group I mGlu receptors and selectively blocks kainate receptor-mediated LTP induction in rat hippocampal mossy fibres.Certificate of Analysis / Safety Data Sheet
References
More et al (2004) Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology 47 46. PMID: 15165833.
Dolman et al (2005) Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors. J.Med.Chem. 48 7867. PMID: 16302825.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: UBP 302, supplier, Selective, potent, kainate, antagonists, Glutamate, Kainate, Receptors, iGluR, Ionotropic, UBP302
Quick Order
Find multiple products by catalog number
Pain Research Guide
Reserve your free copy
Highlights over 280 products for Pain research. Reserve copy
Calcium Imbalance and Neuroprotective Targets
Written by E. Besancon et al
'Calcium Imbalance and Neuro-protective Targets in Cerebral Ischemia & Brain Injury' highlights the key targets involved in stroke, trauma and neurodegeneration.
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.
Therapeutic Strategies in Schizophrenia
Written by J. Lieberman
'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.
New Products in this Area
Positive allosteric modulator of GluA2 receptors
Tocris Events
Win a Kindle
11th Annual Meeting of the International Society for Stem Cell Research
June 12 - 15, 2013
Boston, MA
Booth Number: 213